Table 1 Open in new tab Strategy...

Table 1

Strategy proposed (and adapted) by Schwarz et al. for the therapeutic management of myocardial bridging

	Clinical symptoms	Signs of ischaemia	Initial treatment strategy	Secondary treatment if no improvement
Type A	Yes	No	Reassurance, look for non-cardiac cause	—
Type B	Yes	Yes, by non-invasive stress testing	Beta-blockers, or if contraindicated non-dihydropyridine calcium-channel blockers. Target heart rate: 55–60 bpm at rest, consider ivabradine if not reached.	Intracoronary haemodynamic evaluation → surgery if abnormal
Type C	Yes	Yes, by altered intracoronary haemodynamics	Beta-blockers, or if contraindicated non-dihydropyridine calcium-channel blockers. Target heart rate: 55–60 bpm at rest, consider ivabradine if not reached.	Surgery

	Clinical symptoms	Signs of ischaemia	Initial treatment strategy	Secondary treatment if no improvement
Type A	Yes	No	Reassurance, look for non-cardiac cause	—
Type B	Yes	Yes, by non-invasive stress testing	Beta-blockers, or if contraindicated non-dihydropyridine calcium-channel blockers. Target heart rate: 55–60 bpm at rest, consider ivabradine if not reached.	Intracoronary haemodynamic evaluation → surgery if abnormal
Type C	Yes	Yes, by altered intracoronary haemodynamics	Beta-blockers, or if contraindicated non-dihydropyridine calcium-channel blockers. Target heart rate: 55–60 bpm at rest, consider ivabradine if not reached.	Surgery